AeroClean’s Purgo receives FDA clearance for elimination of SARS-CoV-2

AeroClean announced that, the U.S. Food and Drug Administration has granted AeroClean 510k clearance to update its Purgo air purifier’s indications for use to include the elimination of SARS-CoV-2, the RNA virus that causes COVID-19. The FDA has reviewed the laboratory performance data and confirmed the applicability of Purgo to remove SARS-CoV-2 from the air in indoor environments. The clearance adds SARS-CoV-2 to the list of microorganisms already cleared. As part of AeroClean’s ongoing commitment to improve Indoor Air Quality for a healthier and safer world, the Company has commenced additional efficacy testing on viruses that are known threats to health such as influenza and respiratory syncytial virus.